title: Apolipoprotein E enrichment of immuno-separated chylomicron and chylomicron remnants following saturated fatty acids.
abstract: OBJECTIVE
  We examined the effect of meal fatty acids on lipid and apolipoprotein concentrations of very low density lipoprotein (VLDL) and chylomicron/chylomicron remnants in lipid fractions with a Svedberg flotation rate (Sf) 60-400 and Sf 20-60.
  
  
  RESULTS
  Six healthy middle-aged men received in random order mixed meals enriched with saturated (SFA), polyunsaturated (PUFA) or monounsaturated (MUFA) fatty acids on 3 occasions. VLDL and chylomicron/chylomicron remnants in the lipid fractions were separated by immunoaffinity chromatography against apo B-100. In the Sf 60-400 chylomicron/chylomicron remnants, triacylglycerol and cholesterol concentrations were significantly lower following PUFA compared with SFA and MUFA (P < or = 0.05). Apolipoprotein (apo) E responses were significantly higher after SFA in chylomicron/chylomicron remnants and VLDL compared with PUFA and MUFA (P < 0.007). However, apo B responses (particle number) were higher following MUFA than SFA (P = 0.039 for chylomicron/chylomicron remnants). Composition of the chylomicron/chylomicron remnants (expressed per particle) revealed differences in their triacylglycerol and apo E contents; in the Sf 60-400 fraction, SFA-rich chylomicron/chylomicron remnants contained significantly more triacylglycerol than MUFA (P = 0.028), more apo E than PUFA- and MUFA-rich particles (P < 0.05) and in the Sf 20-60 fraction, more apo E than MUFA (P = 0.009).
  
  
  CONCLUSIONS
  There are specific differences in the composition of chylomicron/chylomicron remnants formed after saturated compared with unsaturated fatty acid-rich meals which could determine their metabolic fate in the circulation and subsequent atherogenicity.
authors.affiliation: Hugh Sinclair Unit of Human Nutrition, School of Food Biosciences, The University of Reading, Reading, Berkshire RG6 6AP, UK. k.g.jackson@reading.ac.uk
authors.forename: Kim G
authors.initials: KG
authors.lastname: Jackson
authors.forename: Emma J
authors.initials: EJ
authors.lastname: Wolstencroft
authors.forename: Paul A
authors.initials: PA
authors.lastname: Bateman
authors.forename: Parveen
authors.initials: P
authors.lastname: Yaqoob
authors.forename: Christine M
authors.initials: CM
authors.lastname: Williams
mesh_terms: D000328:Adult; D053305:Apolipoprotein C-III; D001056:Apolipoproteins C / Q000032:analysis; D001057:Apolipoproteins E / Q000032:analysis*; D053298:Chylomicron Remnants; D002914:Chylomicrons / Q000032:analysis*; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage; D005215:Fasting / Q000097:blood; D005227:Fatty Acids / Q000008:administration & dosage*; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage; D006801:Humans; D008079:Lipoproteins, VLDL / Q000032:analysis; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D053305:Apolipoprotein C-III; D001056:Apolipoproteins C; D001057:Apolipoproteins E; D053298:Chylomicron Remnants; D002914:Chylomicrons; D004042:Dietary Fats, Unsaturated; D005227:Fatty Acids; D005229:Fatty Acids, Monounsaturated; D005231:Fatty Acids, Unsaturated; D008079:Lipoproteins, VLDL; D014280:Triglycerides